Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting

Journal of Viral Hepatitis

Volumn 22, Issue 5, 2015, Pages 504-510

  Idilman, R ^a   Gunsar, F ^b   Koruk, M ^c   Keskin, O ^a   Meral, C E ^b   Gulsen, M ^b   Elhan, A H ^a   Akarca, U S ^b   Yurdaydin, C ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

chronic hepatitis B; entecavir; hepatocellular carcinoma; tenofovir disoproxil fumarate

Indexed keywords

CREATININE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; GUANINE; TENOFOVIR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER DIAGNOSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SIDE EFFECT; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPLICATION; HEPATITIS B, CHRONIC; INCIDENCE; ISOLATION AND PURIFICATION; LIVER NEOPLASMS; METABOLIC CLEARANCE RATE; MIDDLE AGED; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CREATININE; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TENOFOVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84926451842     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12358     Document Type: Article

References (22)

1. Tozun N, Ozdogan OC, Cakaloʇlu Y, et al,. A nationwide prevalence study and risk factors for hepatitis A, B, C and D infections in Turkey. Hepatology 2010; 52 (S1): 697A.
2. Lok AS, McMahon BJ,. Chronic hepatitis B update 2009. Hepatology 2009; 50: 661-662.
3. El-Serag HB,. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
4. Uzunalimoglu O, Yurdaydin C, Cetinkaya H, et al,. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001; 46: 1022-1028.
5. Available at https://organ.saglik.gov.tr/web/. 2013.
6. Liaw YF, Sung JJ, Chow WC, et al,. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
7. Hadziyannis SJ, Tassopoulos NC, Heatcote EJ, et al,. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751.
8. Idilman R, Cinar K, Seven G, et al,. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 2012; 19: 220-226.
9. Heathcote EJ, Marcellin P, Buti M, et al,. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143.
10. Peng CY, Chien RN, Liaw YF,. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-450.
11. Zoutendijk R, Reijnders JGP, Zoulim F, et al,. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62: 760-765.
12. Kim GA, Lim YS, An J, et al,. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 2013; 62: 760-765.
13. Chang TT, Lai CL, Yoon SK, et al,. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.
14. Lai CL, Yuen MF,. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013; 57: 399-408.
15. Singal AK, Salameh H, Kuo YF, Fontana RJ,. Meta-analysis of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38: 98-106.
16. Bozdayi AM, Aslan N, Bozdayi G, et al,. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004; 149: 2115-2129.
17. Marcellin P, Gane E, Tsai N, et al,. Seven years of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical, and serological responses with no detectable resistance. Hepatology 2013; 58 (S): A926.
18. Fattovich G, Bortolotti F, Donato F,. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.
19. Chen CJ, Yang HI, Su J, et al,. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 354: 1001-1010.
20. Hosaka T, Suzuki F, Kobayashi M, et al,. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
21. Zhang Q-Q, An X, Liu YH, et al,. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J 2011; 8: 72.
22. Chen CF, Lee WC, Yang HI, et al,. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 1240-1248.